Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ran Qi
Institutions:
Affiliated Hospital of Jining Medical University,
Jining Medical University
Observed institutions:
Hebei Medical University,
Third Hospital of Hebei Medical University,
Affiliated Hospital of Jining Medical University,
Jining Medical University
ORCID:
0000-0001-5417-7790
Observed ORCID:
0000-0001-5417-7790
OpenAlex ID:
A5010854129
The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials
2023
·
Xiaoyang Duan
, Huazhen Du
, et al.
·
Experimental and Therapeutic Medicine
·
4
PDF
Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
2024
·
Lan-Fang Li
, Ran Qi
, et al.
·
Risk Management and Healthcare Policy
·
2
PDF
Anlotinib plus penpulimab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the perspective of the Chinese healthcare system
2026
·
Gengliang Bai
, Haoyu Yang
, et al.
·
Frontiers in Oncology
PDF
Cost-effectiveness analysis of sintilimab plus chemotherapy versus chemotherapy alone for the first-line treatment of advanced oesophageal squamous cell carcinoma
2022
·
Ran Qi
, Xuyang Nie
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
4
Citation count:
6
H-index:
2
I10-index:
Year
Topic
Type